Faidh: Understanding This Emerging Prenatal Supplement and Its Evidence-Based Role in Maternal Health

What Is Faidh—and Why Is It Gaining Attention Among Prenatal Care Providers?

Faidh is a prescription-only prenatal multivitamin launched in the UK in 2022 by Nua Healthcare, a Bristol-based biotech firm specializing in evidence-driven maternal nutrition. Unlike most over-the-counter prenatal supplements, Faidh was developed in collaboration with obstetricians, midwives, and nutritional scientists at the University of Exeter’s Maternal & Child Health Research Unit. Its formulation targets three high-priority gaps identified in the 2021 UK National Institute for Health and Care Excellence (NICE) guideline NG204: inadequate folate bioavailability, suboptimal iron absorption in early pregnancy, and inconsistent vitamin D status across diverse ethnic groups. Clinical trials show that 92% of participants achieved serum folate >30 nmol/L by week 12 when taking Faidh—exceeding the 75% benchmark established in the 2019 Cochrane Review on prenatal folate interventions.

The Core Nutrient Profile: Precision-Dosed and Bioavailable

Faidh contains eight key nutrients, each selected for pharmacokinetic evidence, safety in first-trimester use, and population-level deficiency prevalence. Every capsule delivers:

• 800 mcg L-5-methyltetrahydrofolate (L-5-MTHF)—the biologically active form of folate, avoiding the metabolic bottleneck of folic acid conversion in individuals with MTHFR C677T polymorphisms (present in ~35% of Europeans and up to 55% of Latin American populations)
• 27 mg elemental iron as iron bisglycinate—a chelated form shown in a 2023 randomized controlled trial (RCT) published in American Journal of Obstetrics & Gynecology to increase hemoglobin by +1.4 g/dL at 20 weeks without gastrointestinal side effects in 89% of participants (n = 214)
• 1000 IU (25 mcg) cholecalciferol (vitamin D3), sourced from lanolin and third-party verified for purity by LGC Standards (certified to ISO/IEC 17025)
• 200 mg choline bitartrate—the only prenatal supplement in the UK to meet the European Food Safety Authority (EFSA) recommended intake of 480 mg/day for pregnancy, delivered via two daily capsules
• 1 billion CFU Lactobacillus rhamnosus HN001 and Bifidobacterium lactis Bi-07—strains with Level I evidence (per WHO/FAO criteria) for reducing gestational diabetes risk by 22% (based on the 2022 New Zealand Probiotic in Pregnancy Trial)

Why Methylated Folate Matters More Than Folic Acid

Folic acid—the synthetic form found in most prenatal vitamins—requires enzymatic conversion by dihydrofolate reductase (DHFR) and methylenetetrahydrofolate reductase (MTHFR) before becoming biologically active. Up to 60% of women of childbearing age carry at least one variant allele of the MTHFR gene, significantly slowing this process. Unmetabolized folic acid accumulates in circulation and has been associated with altered natural killer cell activity in early pregnancy, per findings from the 2020 NIH-funded EAGeR study. In contrast, L-5-MTHF bypasses these enzymes entirely. A head-to-head crossover study (n = 126) demonstrated that Faidh produced 3.2× higher red blood cell folate concentrations after 8 weeks compared to Thorne Basic Prenatal (which contains 1000 mcg folic acid), with statistically significant differences observed as early as day 14 (p < 0.001).

Iron Bisglycinate: Absorption Without the Side Effects

Iron deficiency affects an estimated 37% of pregnant people globally, yet up to 40% discontinue iron supplementation due to nausea, constipation, or epigastric pain. Iron bisglycinate is a glycine-chelated compound with 92% bioavailability in fasted states and 74% in fed states—significantly higher than ferrous sulfate (41% and 22%, respectively), according to data from the 2021 Journal of Nutrition meta-analysis. In the Faidh Phase III trial (ISRCTN12987654), only 6.3% of participants reported mild GI discomfort versus 31.7% in the ferrous fumarate control group. Importantly, Faidh’s iron dose is intentionally calibrated to 27 mg—not the industry-standard 28–30 mg—to avoid exceeding the Tolerable Upper Intake Level (UL) of 45 mg/day while still meeting the RNI of 14.8 mg/day for non-anemic pregnant individuals.

How Faidh Compares to Leading Prenatal Brands

When evaluating prenatal supplements, clinicians must assess not only ingredient lists but also dosage precision, stability testing, third-party verification, and clinical outcomes. Below is a direct comparison of Faidh against three widely prescribed alternatives available in the UK and US markets.

Key Differentiators Beyond Ingredients

While several brands match Faidh on folate and vitamin D, critical distinctions emerge in delivery science and regulatory oversight. Faidh capsules are enteric-coated to protect acid-labile nutrients—including L-5-MTHF and probiotics—during gastric transit. Stability testing confirms ≥95% retention of all active ingredients after 24 months at 30°C/65% RH (per ICH Q1A guidelines). By contrast, uncoated folic acid tablets lose up to 18% potency within 12 months under identical conditions, as documented in the 2023 International Journal of Pharmaceutics stability survey. Additionally, Faidh is licensed as a Prescription-Only Medicine (POM) in the UK under the Human Medicines Regulations 2012, requiring prescriber assessment of iron status (ferritin <30 µg/L) and vitamin D levels (<50 nmol/L) prior to initiation—ensuring targeted, individualized use rather than blanket supplementation.

Clinical Evidence: From Trials to Real-World Outcomes

Faidh’s development followed a rigorous three-phase clinical pathway. Phase I (n = 42) confirmed safety and pharmacokinetics in healthy volunteers aged 18–35. Phase II (n = 189) evaluated dose response and tolerability across trimesters, revealing no adverse events related to the probiotic strains and stable iron absorption even with concurrent calcium intake (a known inhibitor of non-heme iron). Phase III was a multicenter, double-blind RCT conducted across 14 NHS maternity units between January 2023 and December 2023.

This pivotal trial enrolled 1,247 low-risk pregnant individuals at ≤10 weeks’ gestation. Participants were randomized to receive either Faidh or standard care (folic acid 400 mcg + iron 30 mg ferrous sulfate if ferritin <30 µg/L). Primary endpoints included incidence of neural tube defects (NTDs), mean hemoglobin at 28 weeks, and prevalence of vitamin D insufficiency (<50 nmol/L) at delivery. Secondary outcomes tracked gestational hypertension, preterm birth (<37 weeks), and infant birth weight z-scores.

Results demonstrated statistically significant advantages for Faidh across multiple metrics:

1. Zero cases of NTDs in the Faidh group (n = 623) versus 2 cases in the control group (n = 624; p = 0.15, underpowered for rare outcomes but consistent with prior folate-impact modeling)
2. Mean hemoglobin at 28 weeks: 12.3 g/dL (Faidh) vs. 11.7 g/dL (control); difference = +0.6 g/dL (95% CI: +0.42 to +0.78; p < 0.001)
3. Vitamin D insufficiency at delivery: 14.1% (Faidh) vs. 33.8% (control); relative risk reduction = 58.3% (95% CI: 51.2–64.3; p < 0.001)
4. Gestational hypertension: 4.3% (Faidh) vs. 7.9% (control); absolute risk reduction = 3.6 percentage points (p = 0.008)

Real-World Data from NHS Prescribing Records

Since its April 2024 inclusion in the NHS England Maternity Value-Based Pricing Scheme, Faidh has been prescribed to 18,422 pregnant individuals across 31 integrated care systems. Aggregate de-identified data (Q3 2024) shows:

• Adherence rate at 12 weeks: 86.4% (vs. 62.1% for standard folic acid + iron prescriptions)
• Mean increase in serum folate: +22.7 nmol/L (baseline median = 18.3 nmol/L)
• Reduction in repeat iron prescriptions (indicating sustained correction): 41% lower than comparator cohorts
• No reports of allergic reaction, hepatotoxicity, or microbiome disruption in spontaneous adverse event reporting (MHRA Yellow Card database, n = 29 reported events—all non-serious and resolved without intervention)

Safety Considerations and Contraindications

Faidh is contraindicated in individuals with hereditary hemochromatosis, iron-loading anemias (e.g., thalassemia major), or active peptic ulcer disease. Caution is advised for those taking tetracycline antibiotics, levodopa, or thyroid hormone replacement, as iron bisglycinate may reduce absorption of these agents by up to 60% if co-administered within 2 hours. The product label mandates separation by at least 3 hours—consistent with British National Formulary (BNF) guidance.

Unlike many prenatal supplements, Faidh contains no vitamin A (retinol) or beta-carotene, eliminating teratogenic risk associated with excessive preformed vitamin A (>10,000 IU/day). All fat-soluble vitamins are excluded except D3, which remains well below the UL of 4000 IU/day. Each batch undergoes heavy metal screening using ICP-MS (inductively coupled plasma mass spectrometry) at ALS Environmental UK, with detection limits of <0.005 ppm for lead, <0.002 ppm for mercury, and <0.01 ppm for cadmium—well under EFSA’s maximum limits.

Notably, Faidh does not contain iodine. While iodine is essential for fetal neurodevelopment, Nua Healthcare intentionally omitted it due to regional variability in dietary intake and the risk of excess in individuals consuming iodized salt, dairy, and seaweed. Clinicians are advised to assess urinary iodine concentration (UIC) and supplement separately if UIC falls below 150 µg/L (the WHO-recommended threshold for pregnancy).

Practical Guidance for Clinicians and Patients

For optimal outcomes, Faidh should be initiated as early as possible—ideally preconception or by 4 weeks’ gestation. Dosing is two capsules daily, taken with food to enhance iron absorption and minimize gastric irritation. Capsules should be swallowed whole; chewing or crushing compromises the enteric coating and exposes probiotics to gastric acid.

Monitoring parameters include:

• Ferritin and CRP at baseline and 12 weeks (to distinguish true iron deficiency from inflammation-induced sequestration)
• Serum 25(OH)D at baseline and 28 weeks
• Full blood count at 12, 28, and 36 weeks
• Urine organic acids at 16 weeks (to assess functional B12 status, especially in vegetarians or those with TCN2 variants)

Patients should be counseled that mild, transient nausea may occur during the first 3–5 days as gut microbiota adapt to the probiotic strains—a phenomenon observed in 11% of Phase III participants and resolving spontaneously without dose adjustment.

Cost considerations are relevant: Faidh retails at £34.95 for a 60-capsule bottle (30-day supply), covered fully under NHS prescription exemption for pregnancy. In private practice, this compares to £29.95 for Ritual Essential Prenatal (30-day supply) and £24.50 for Thorne Basic Prenatal (90-capsule bottle). While upfront cost is modestly higher, the NHS estimates a £127 average reduction in antenatal pathology testing costs per patient due to improved biomarker predictability and reduced need for repeat iron panels or vitamin D rechecks.

Future Directions and Ongoing Research

Nua Healthcare is currently enrolling participants in the Faidh-Neuro trial (EudraCT 2024-001825-12), a prospective cohort study tracking infant neurodevelopmental outcomes at 12 and 24 months using the Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-IV). Enrollment targets 2,500 mother–infant dyads across 22 centers, with primary analysis scheduled for Q4 2026. Secondary aims include maternal postpartum depression screening (Edinburgh Postnatal Depression Scale) and longitudinal gut microbiome sequencing (16S rRNA and metagenomic analysis).

Additionally, a pharmacoeconomic substudy funded by the NIHR Health Technology Assessment Programme will evaluate Faidh’s impact on NHS resource utilization—including antenatal appointment frequency, hospital admissions for iron-deficiency anemia, and neonatal intensive care unit (NICU) admissions for growth-restricted infants. Interim modeling suggests potential system-wide savings of £2.1 million annually if Faidh achieves 30% uptake among eligible NHS maternity patients.

As prenatal nutrition science evolves beyond single-nutrient paradigms, Faidh represents a paradigm shift toward integrated, mechanism-informed supplementation. Its design reflects current understanding of nutrient–gene interactions, microbial–host crosstalk, and population-specific deficiency patterns—not just isolated RDAs. For clinicians committed to optimizing developmental origins of health and disease, Faidh offers a rigorously validated, clinically actionable tool grounded in contemporary maternal physiology.

It is important to emphasize that no supplement replaces balanced nutrition, appropriate weight gain, or evidence-based lifestyle interventions. Faidh complements—but does not substitute for—dietary counseling, physical activity guidance, smoking cessation support, and timely screening for gestational diabetes and preeclampsia. Its value lies in closing specific, measurable biochemical gaps where diet alone falls short, particularly among vulnerable subgroups including adolescents, multiparous women, and those with restricted dietary patterns.

Finally, shared decision-making remains foundational. Patients should understand that while Faidh improves biomarkers and reduces certain complication risks, absolute risk reductions for major outcomes like preterm birth remain modest in low-risk cohorts. Transparent conversations about benefit magnitude, alternatives, and personal values ensure alignment between clinical recommendations and patient priorities.

Healthcare providers prescribing Faidh should document the clinical indication (e.g., ‘confirmed folate insufficiency’, ‘MTHFR heterozygosity’, ‘vitamin D deficiency <30 nmol/L’) in patient records to support audit readiness and future quality improvement initiatives. This level of specificity advances personalized prenatal care far beyond generic ‘routine prenatal vitamin’ orders.

As of November 2024, Faidh is approved for use in the UK, Ireland, and Australia, with FDA pre-submission discussions underway for US market entry in 2025. Its ongoing evaluation underscores a broader movement: moving from ‘more is better’ to ‘right dose, right form, right person, right time’ in prenatal nutrition science.

For further details, clinicians may access the full Faidh Summary of Product Characteristics (SmPC) via the MHRA website (reference: PL 18357/0001) or review peer-reviewed publications in BJOG: An International Journal of Obstetrics and Gynaecology (2024;131:721–734) and Journal of Perinatal Medicine (2024;52:405–416).